Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin with induction, consolidation, and maintenance therapy in newly diagnosed FLT3-mutated acute myeloid leukemia
2016-004440-12Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoint: Safety. Started Sep 2017; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-004440-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004440-12.